Condition: Allergic Rhinitis · Sponsor: Zheng Liu
The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.
This description comes directly from the study's public registry record.
Zheng Liu, Doctor · 86 027 83663807 · zhengliuent@hotmail.com
Ming Zeng, Doctor · 86 027 83663807 · zmsx77@163.com
Always discuss trial participation with your own doctor first.
| Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology | Wuhan, Hubei, China | Recruiting |
| Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06462417